Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Long-Term Outcomes of Vedolizumab and TNF Inhibitors in Patients with Ulcerative Colitis

  • By

  • Siddharth Singh

  • Jonas Söderling

  • Anders Forss

  • Mathias Rask-Andersen

  • Jonas Halfvarson

  • Åsa H. Everhov

  • Jonas F. Ludvigsson

  • Ola Olén

  • SWIBREG study group

  • Malin Olsson

  • Pär Myrelid

  • Henrik Hjortswang

  • Jonas Bengtsson

  • Hans Strid

  • Marie Andersson

  • Susanna Jäghult

  • Caroline Nordenvall

  • Charlotte Hedin

  • Martin Rejler

  • Olof Grip

  • Ulrika L Fagerberg

  • Karl Mårild

  • Johann Hreinsson

  • Pontus Karling

  • September 25, 2026

Share

Clinical Scorecard: Comparative Long-Term Outcomes of Vedolizumab and TNF Inhibitors in Patients with Ulcerative Colitis

At a Glance

CategoryDetail
ConditionUlcerative Colitis
Key MechanismsComparison of long-term outcomes between vedolizumab and TNF inhibitors (infliximab, adalimumab).
Target PopulationBiologic-naive patients with moderate-to-severe ulcerative colitis.
Care SettingNationwide cohort study using population-based registers.

Key Highlights

  • Vedolizumab showed higher clinical and endoscopic remission rates than adalimumab in biologic-naive patients.
  • Long-term outcomes include hospitalization rates, surgery, and corticosteroid use.
  • Study utilized data from multiple national health registers for comprehensive follow-up.

Guideline-Based Recommendations

Diagnosis

  • Patients identified by ICD-10 codes or biopsy reports suggestive of inflammatory bowel disease.

Management

  • First-line therapy options include infliximab, adalimumab, or vedolizumab.

Monitoring & Follow-up

  • Follow-up for at least 2 years post-initiation of advanced therapy to assess long-term outcomes.

Risks

  • Serious infections defined as hospitalization for infection as primary diagnosis.

Patient & Prescribing Data

Biologic-naive patients with ulcerative colitis initiating advanced therapy.

Long-term outcomes vary based on the choice of first-line therapy.

Clinical Best Practices

  • Ensure comprehensive follow-up using national health registers.
  • Consider treatment sequencing and optimization based on individual patient response.

Related Resources & Content

Original Source(s)

Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis

  • by Siddharth Singh, Jonas Söderling, Anders Forss, Mathias Rask-Andersen, Jonas Halfvarson, Åsa H. Everhov, Jonas F. Ludvigsson, Ola Olén, SWIBREG study group, Malin Olsson, Pär Myrelid, Henrik Hjortswang, Jonas Bengtsson, Hans Strid, Marie Andersson, Susanna Jäghult, Caroline Nordenvall, Charlotte Hedin, Martin Rejler, Olof Grip, Ulrika L Fagerberg, Karl Mårild, Johann Hreinsson, Pontus Karling

  • September 25, 2026

Related Content

Correction: Hepaticojejunostomy bile leakage and aberrant biliary anatomy during robotic pancreatoduodenectomy: intraoperative detection and management

Correction: Defining post–colon capsule endoscopy colorectal cancer (pCCECRC)—an International Capsule Endoscopy Research (iCARE) group consensus statement

Low Cholesterol and Liver Risk—The Mechanism Matters